| abstract |
The invention describes a conjugate consisting of a variant of insulin-like growth factor I (IGF-I) and one or two polyethylene glycol groups, characterized in that the specified variant IGF-I has up to three amino acid substitutions in positions 27, 37, 65, 68 IGF-I, of which one or two of these amino acids are lysine, and the amino acid at position 27 is a polar amino acid, but not lysine, and is conjugated to the primary amino group (amino groups) of the indicated lysine (lysines) nN (groups) of the polyethylene glycol is 20-100 kDa. This conjugate is useful for treating neurodegenerative disorders, such as Alzheimer's disease. |